By vgreene, 1 June, 2017 GI Endo DM nephropathy retinopathy or neuropathy 3 20 yr duration or other vascular dz 3 severe cirrhosis 3 liver tumors hepatocellular adenoma hepatoma 3 1
By vgreene, 1 June, 2017 Immune SLE antiphospholipid antibody or unknown 3 severe thrombocytopenia initiating 3 1 solid organ txp on immunosuppressive tx w risks hx of nontraumatic fx 3 RA immunosuppressive tx w risks hx of nontraumatic fx 3 2
By vgreene, 1 June, 2017 CV Resp DVT PE hx anticoag tx ppx dose w risk factors 3 current hx IHD 3 stroke 3 multiple risk factors for CV dz older age smoking DM HTN low HDL high LDL high TGs 3 HTN systolic 160 or diastolic 100 mm Hg or assoc w vascular dz 3 1 peripartum cardiomyop
By vgreene, 1 June, 2017 Heme Onc current breast CA 4 past breast CA w o dz x5y 3 SLE w severe thrombocytopenia initiating 3 1 thrombophilia factor V Leiden mutation prothrombin mutation protein S C or antithrombin deficiencies or antiphospholipid syndrome 3 sickle cell dz if sev
By vgreene, 1 June, 2017 No routine f u visit required assess the following at other routine visits 5 nbsp nbsp satisfaction concerns w method nbsp nbsp health status changes nbsp nbsp weight changes
By vgreene, 1 June, 2017 Back up contraception abstinence required x7 days after placement in certain situations Use barrier method or abstain x7 days if nbsp nbsp implant placed 5 days after start of menses4 nbsp nbsp amenorrheic not post partum 4 nbsp nbsp 21 days post partum a
